Spots Global Cancer Trial Database for wm
Every month we try and update this database with for wm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | NCT00422656 | Waldenstrom's M... | Perifosine | 18 Years - | Dana-Farber Cancer Institute | |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | NCT01732926 | Indolent Non-Ho... | Idelalisib Rituximab Bendamustine Placebo | 18 Years - | Gilead Sciences | |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | NCT01732913 | Indolent Non-Ho... | Placebo Rituximab Idelalisib | 18 Years - | Gilead Sciences | |
| Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM) | NCT00422799 | Waldenstrom's M... | Bortezomib Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | NCT04043845 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... | Ibrutinib LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia | NCT01779167 | Waldenstrom Mac... | Thalidomide Lenalidomide Rituximab | 18 Years - | Weill Medical College of Cornell University | |
| Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia | NCT04624906 | Waldenstrom Mac... | Acalabrutinib Bendamustine Rituximab | 18 Years - | Sunnybrook Health Sciences Centre | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | NCT03601819 | Lymphoma, T-Cel... Lymphoma, T-Cel... Chronic Lymphoc... Lymphoprolifera... Waldenstrom Mac... Lymphoplasmacyt... Mantle Cell Lym... | Pacritinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | NCT04043845 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... | Ibrutinib LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia | NCT00936611 | Waldenstrom's M... | LBH589 | 18 Years - | Dana-Farber Cancer Institute | |
| Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | NCT03786926 | Lymphoma | HMPL-689 | 18 Years - | Hutchmed | |
| An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia | NCT02180724 | Waldenström Mac... | Acalabrutinib (... Acalabrutinib (... | 18 Years - 130 Years | Acerta Pharma BV | |
| LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia | NCT00936611 | Waldenstrom's M... | LBH589 | 18 Years - | Dana-Farber Cancer Institute | |
| Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia | NCT01470196 | Waldenstrom's M... | Dexamethasone Carfilzomib Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia | NCT02165397 | Waldenström's M... | Ibrutinib Placebo Rituximab | 18 Years - | Pharmacyclics LLC. | |
| Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia | NCT01779167 | Waldenstrom Mac... | Thalidomide Lenalidomide Rituximab | 18 Years - | Weill Medical College of Cornell University | |
| Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia | NCT04624906 | Waldenstrom Mac... | Acalabrutinib Bendamustine Rituximab | 18 Years - | Sunnybrook Health Sciences Centre | |
| Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies | NCT04277637 | Mature B-Cell M... | BGB-11417 Zanubrutinib obinutuzumab | 18 Years - | BeiGene | |
| A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | NCT03893682 | Chronic Lymphoc... Small Lymphocyt... Non-Hodgkin's L... | CG-806 | 18 Years - | Aptose Biosciences Inc. | |
| Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia | NCT02165397 | Waldenström's M... | Ibrutinib Placebo Rituximab | 18 Years - | Pharmacyclics LLC. | |
| Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia | NCT01779167 | Waldenstrom Mac... | Thalidomide Lenalidomide Rituximab | 18 Years - | Weill Medical College of Cornell University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
